Research and Markets: Protein Kinase Therapeutics in Oncology - Where To Commercialize? Analyses 133 Identified Targets of Protein Kinase Drugs, Organized Into 200 Drug Target Profiles
DUBLIN--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/ef5944/protein_kinase_the) has announced the addition of the "Protein Kinase Therapeutics in Oncology - Where to Commercialize?" report to their offering. This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications. The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by: * Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives * Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties * Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities * Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities * Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment This report will also be an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized. Key Topics Covered: * 1 Executive Summary * 2 About Cancer Highlights * 3 Methodologies * 4 Overview * 5 Introduction * 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment * 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? * 8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type * 9 Selecting Cancer Indications for Protein Kinase Therapeutics * 10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator * 11 Disclaimer * 12 Drug Index * 13 Company Index * 4.1 List of Figures * 4.1 List of Figures Companies Mentioned: * AB Science * Abbott * Bayer * Cancer Research Technology * Celgene * Exelixis * Galapagos * Insmed * Johnson & Johnson * Kirin Pharma * KuDOS * Kyowa Hakko Kirin * Novogen * Oncalis * Pfizer * Provid * QLT * Quantum Pharmaceuticals * Ras Therapeutics * Sareum * SBIO * Scancell * Schering-Plough * ToolGen * TopoTarget * UCB * VasGene Therapeutics * ViroMed * Wyeth * Xencor For more information visit http://www.researchandmarkets.com/research/ef5944/protein_kinase_the Research and Markets Laura Wood, Senior Manager, press@researchandmarkets.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Copyright Business Wire 2009
